The enhanced infiltration and activation of CD8+ T cells after multimodal tumor treatment and cell death modulation with zVAD-fmk had given hints that the observed tumor growth retardation by zVAD-fmk is dependent on T cells. This evidence concerns the gene CD8A and neoplasm.